Karyopharm Therapeutics Inc.

符号: KPTI

NASDAQ

1.37

USD

今天的市场价格

-0.9064
市盈率
-0.0160
PEG比率
157.64M
MRK市值
0.00%
DIV收益率

Karyopharm Therapeutics Inc. (KPTI) 财务报表

Q: 什么是 Karyopharm Therapeutics Inc. (KPTI) 总资产是多少？

Karyopharm Therapeutics Inc. (KPTI) 总资产为 .

Download

年度季度

线性对数

在图表中，您可以看到的动态默认数字 Karyopharm Therapeutics Inc. (KPTI). 的默认数据。公司收入显示 53.512 M 的平均值，即 2.463 % 增长率。整个期间的平均毛利润为 52.035 M，即 2.464 %. 平均毛利率为 0.987 %. 公司去年的净收入增长率为 -0.134 %，等于 -0.299 % % 整个公司历史的平均增长率.,

年度季度

10Y 20Y 30Y 40Y

资产负债表

深入分析 Karyopharm Therapeutics Inc. 的财务轨迹，我们可以看到其平均资产增长率。有趣的是，这一增长率为，反映了公司的高点和低点。与季度相比，这一数字调整为0. 回顾过去一年，总资产变化为 -0.329. 在流动资产领域，KPTI 的报告货币为233.921. 这些资产中的很大一部分，即 192.103 是现金和短期投资。与去年的数据相比，该部分的变化率为-0.309%. 公司的长期投资虽然不是其重点，但以报告货币计算的0.301（如果有的话）为0.301。这表明与上一报告期相比，-52.449% 的差异反映了公司的战略转变. 公司的债务概况显示，以报告货币计算的长期债务总额为 170.919. 这一数字表明，0.023% 的年同比变化. 股东权益总额所体现的股东价值是以报告货币计算的 -136.206. 这方面的年同比变化率为 7.178%. 深入了解公司财务信息后，会发现更多细节。应收账款净额的估值为26.962，存货估值为 3.04，商誉估值为 0（如有. 无形资产总额（如果有）按 0 估值. 应付账款和短期债务分别为 3.12 和 3.31. 债务总额为177.02，债务净额为 124.13. 其他流动负债为 63.05，加上总负债 376.64. 最后，如果存在推荐股票，则其估值为 0.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014	2012
balance-sheet.row.cash-and-short-term-investments	897.57	192.1	278	228.6	273.5	264	328.2	146.5	129.6	175.6	205.7	156	0.4	6.5
balance-sheet.row.short-term-investments	636.07	139.2	142.8	38.2	163.3	133.1	210.2	77.5	79.9	117.3	55.1	0	0	0
balance-sheet.row.net-receivables	132.37	27	47.1	22.5	12.9	7.9	0	0	0	0	0	0	0	0
balance-sheet.row.inventory	13.65	3	4.2	4.1	2.6	0.3	0	0	0	0	0	0	0	0
balance-sheet.row.other-current-assets	226.73	11.8	19.8	2.9	0.6	1.5	6.4	2	2.1	2	2	2	0.6	0.4
balance-sheet.row.total-current-assets	1069.53	233.9	326.8	258.1	289.5	273.7	334.6	148.4	131.6	177.6	207.8	158	1	6.9
balance-sheet.row.property-plant-equipment-net	23.05	4.9	7.4	1.6	2.2	3	3.9	2.2	2.8	3.5	2.8	0.2	0.3	0.3
balance-sheet.row.goodwill	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.intangible-assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.goodwill-and-intangible-assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.long-term-investments	1.7	0.3	0.6	0.6	24.2	2	2	29.4	45.4	33.9	8.7	0	0	0
balance-sheet.row.tax-assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.other-non-current-assets	39.74	1.3	23.4	44.9	-2.9	16.2	0.7	0.3	0.5	0.5	1.2	0	0	0
balance-sheet.row.total-non-current-assets	64.5	6.5	31.4	47.2	23.5	21.3	6.6	31.9	48.7	37.8	12.6	0.3	0.4	0.4
balance-sheet.row.other-assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-assets	1134.03	240.4	358.2	305.3	313.1	295	341.2	180.3	180.4	215.4	220.3	158.2	1.3	7.2
balance-sheet.row.account-payables	15.4	3.1	2.8	1.6	4.5	1	4.3	5.7	4.8	3.8	6.3	1.7	1.1	1.1
balance-sheet.row.short-term-debt	12.56	3.3	2.9	2.3	1.9	1.6	32.9	21.7	0	0	0	0.8	0.8	0.8
balance-sheet.row.tax-payables	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.long-term-debt-total	686.92	170.9	170.1	169.3	117.9	109.9	102.7	0	0	0	0	0	0	0
Deferred Revenue Non Current	530.39	132.5	132.7	133	73.1	4.5	4.5	0	0	0	0	0.4	0	0
balance-sheet.row.deferred-tax-liabilities-non-current	-395.13	-	-	-	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.other-current-liab	172.27	63	60.3	0.7	-6.4	41.4	0.3	0.1	11.7	11.3	6	0.3	0	0
balance-sheet.row.total-non-current-liabilities	1358.64	307.2	374.8	385	262.2	245.2	111.1	1.4	1.7	1.9	1.2	0.4	27.3	17.8
balance-sheet.row.other-liabilities	-123.63	0	-65.9	-73.7	0	-46.4	0	0	0	0	0	0	0	0
balance-sheet.row.capital-lease-obligations	25.52	2.8	9	11.3	13.2	14.8	0	0	0	0	0	0	0	0
balance-sheet.row.total-liab	1487.05	376.6	374.8	385	262.5	245.2	158	50.8	18.1	17.1	13.5	3.3	29.2	19.9
balance-sheet.row.preferred-stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.common-stock	0.05	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.retained-earnings	-5721	-1487	-1343.9	-1178.6	-1069.6	-873.3	-673.7	-495.3	-366.1	-256.5	-138.3	-62.6	-28.6	-12.7
balance-sheet.row.accumulated-other-comprehensive-income-loss	-2.1	-0.2	-0.6	0.2	0.5	0	-0.2	-0.2	-0.3	-0.3	0	-0.3	-0.2	-0.1
balance-sheet.row.other-total-stockholders-equity	5370.03	1351	1327.9	1098.8	1119.6	923.1	857.2	625	528.6	455.2	345.2	217.8	1	0.2
balance-sheet.row.total-stockholders-equity	-353.02	-136.2	-16.7	-79.7	50.5	49.8	183.2	129.5	162.2	198.4	206.8	154.9	-27.9	-12.7
balance-sheet.row.total-liabilities-and-stockholders-equity	1134.03	240.4	358.2	305.3	313.1	295	341.2	180.3	180.4	215.4	220.3	158.2	1.3	7.2
balance-sheet.row.minority-interest	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-equity	-353.02	-136.2	-16.7	-79.7	50.5	49.8	183.2	-	-	-	-	-	-	-
balance-sheet.row.total-liabilities-and-total-equity	1134.03	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Investments	636.37	139.5	142.8	38.2	187.5	135.1	212.2	106.9	125.3	151.2	63.8	0	0	0
balance-sheet.row.total-debt	696.11	177	173	169.3	117.9	109.9	102.7	0	0	0	0	0	0	0
balance-sheet.row.net-debt	434.6	124.1	37.8	-21.2	32	-19	-15.4	-69	-49.7	-58.4	-150.6	-156	-0.4	-6.5

现金流量表

在 Karyopharm Therapeutics Inc. 的财务状况中，自由现金流在过去一段时间内发生了显著变化，呈现出 0.380 的转变。该公司最近通过发行 1.12 扩大了股本，与上一年相比出现了0.000 的差异. 有趣的是，公司的部分股票，特别是 0，是由公司自己回购的。这一举动导致0.000 比上一年有所变化。同时，以报告货币计算，公司的应付账款目前为 0.35. 公司的投资活动产生了现金使用净额，按报告货币计算达到7940000.000. 与上一年相比， -1.076 发生了变化. 在同一时期，公司记录了 0.53, 0 和 0，这对于了解公司的投资和还款策略具有重要意义. 公司的融资活动导致使用的现金净额为0.000，同比差异为0.000. 此外，公司还将0 用于向股东分红。与此同时，该公司还采取了其他财务措施，即 1.12，这也对其在此期间的现金流产生了重大影响. 这些组成部分合在一起，全面反映了公司的财务状况和现金流管理的战略方针。

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014	2012
cash-flows.row.net-income	-143.1	-143.1	-165.3	-124.1	-196.3	-199.6	-178.4	-129	-109.6	-118.2	-75.8	-33.9	-15.9	-10.3
cash-flows.row.depreciation-and-amortization	0.53	0.5	0.6	0.8	1	1	0.7	0.7	0.7	0.6	0.3	0.1	0.1	0.1
cash-flows.row.deferred-income-tax	5.92	-1.1	0	1.5	0.9	-1.4	0	0	0	1.8	0	0	0	0
cash-flows.row.stock-based-compensation	21.71	21.7	35.4	29.8	24.4	15.3	17.3	20.4	22.3	17.1	14.2	3.8	0.7	0
cash-flows.row.change-in-working-capital	31.41	31.4	-20	-23.2	1.4	-13.3	-0.2	33	1	4	9.7	-0.4	-0.4	1.7
cash-flows.row.account-receivables	20.12	20.1	-5.1	-9.6	-5	-7.9	0	0	0	0	0	0	0	0
cash-flows.row.inventory	1.18	1.2	-0.1	-1.5	-2.6	-0.3	0	0	0	0	0	0	0	0
cash-flows.row.account-payables	0.35	0.3	1.2	-2.8	3.5	-3.3	-1.4	0.9	0.9	-2.4	4.5	0.7	-0.1	1.1
cash-flows.row.other-working-capital	-0.7	9.8	-16	-9.3	5.5	-1.8	1.2	32.1	0	6.4	5.2	-1	-0.3	0.5
cash-flows.row.other-non-cash-items	-9.19	-2.2	-0.3	8.1	8.4	7.2	1.4	1.2	1.2	0.7	0.1	0.1	0	0
cash-flows.row.net-cash-provided-by-operating-activities	-92.72	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.investments-in-property-plant-an-equipment	0	0	-0.1	-5.7	-0.1	-0.2	-2.4	-0.1	-0.1	-1.4	-2.8	-0.1	-0.1	-0.4
cash-flows.row.acquisitions-net	0	0	104.3	5.5	53.5	-78.7	0	0	0	0	0	0	0	0
cash-flows.row.purchases-of-investments	-159.15	-159.2	-226	-45.2	-274.6	-178.5	-242.8	-98.4	-134.7	-305.2	-63.8	0	0	0
cash-flows.row.sales-maturities-of-investments	167.09	167.1	121.9	192.8	221	257.1	137.5	115.5	159.4	215.9	0	0	0	0
cash-flows.row.other-investing-activites	-18.9	0	-104.3	-5.5	-53.5	78.7	0	0	0	-0.1	-0.4	0	0	0
cash-flows.row.net-cash-used-for-investing-activites	7.94	7.9	-104.3	141.8	-53.7	78.5	-107.7	17.1	24.6	-90.8	-67	-0.1	-0.1	-0.4
cash-flows.row.debt-repayment	0	0	0	-60	0	0	0	0	0	0	0	0	0	0
cash-flows.row.common-stock-issued	1.12	1.1	189.8	9.9	161.8	46.2	145.7	74.9	50.6	92.1	112.8	113.2	0	0
cash-flows.row.common-stock-repurchased	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.dividends-paid	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.other-financing-activites	1.12	1.1	4	123.7	10.3	78.1	170.4	0.9	0.6	0.6	0.3	72.8	9.5	12
cash-flows.row.net-cash-used-provided-by-financing-activities	39.69	1.1	193.7	73.6	172.1	124.3	316.1	75.7	51.2	92.7	113.1	185.9	9.5	12
cash-flows.row.effect-of-forex-changes-on-cash	-0.03	0	-0.5	0	0.3	0	-0.1	0.2	-0.1	-0.1	0	0	0	0
cash-flows.row.net-change-in-cash	-83.61	-83.4	-60.6	108.3	-41.6	12	49.3	19.3	-8.7	-92.3	-5.4	155.6	-6.1	3.1
cash-flows.row.cash-at-end-of-period	264.86	52.9	136.9	197.4	89.1	130.7	118.7	69	49.7	58.4	150.6	156	0.4	6.5
cash-flows.row.cash-at-beginning-of-period	348.48	136.3	197.4	89.1	130.7	118.7	69.5	49.7	58.4	150.6	156	0.4	6.5	3.4
cash-flows.row.operating-cash-flow	-92.72	-92.7	-149.6	-107.1	-160.2	-190.8	-159.1	-73.7	-84.4	-94	-51.4	-30.3	-15.5	-8.5
cash-flows.row.capital-expenditure	0	0	-0.1	-5.7	-0.1	-0.2	-2.4	-0.1	-0.1	-1.4	-2.8	-0.1	-0.1	-0.4
cash-flows.row.free-cash-flow	-92.72	-92.7	-149.7	-112.8	-160.4	-191	-161.5	-73.8	-84.5	-95.4	-54.3	-30.3	-15.6	-8.9

利润表行

Karyopharm Therapeutics Inc. 的收入与上期相比变化了 -0.070%。据报告, KPTI 的毛利润为 140.56。该公司的营业费用为 270.1，与上年相比变化了 -8.149%. 折旧和摊销费用为 0.53，与上一会计期间相比变化了 -0.767%. 营业费用报告为 270.1，显示-8.149% 的同比变化。销售和营销费用为 0, 其中 0.000% 与上年相比发生了变化。基于近期数据的EBITDA为 0，同比增长0.089%. 营业收入为 -129.54，与上年相比变化了-0.089%. 净利润的变化率为 -0.134%。去年的净收入为-143.1.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014	2012
income-statement-row.row.total-revenue	146.03	146	157.1	209.8	108.1	40.9	30.3	1.6	0.2	0.3	0.2	0.4	0.6	0.2
income-statement-row.row.cost-of-revenue	5.02	5.5	5.2	3.4	2.7	2.4	0	0	0	0	0	0	0	0
income-statement-row.row.gross-profit	141.01	140.6	151.9	206.4	105.4	38.5	30.3	1.6	0.2	0.3	0.2	0.4	0.6	0.2
income-statement-row.row.gross-profit-ratio	0	0	0	0	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.research-development	138.67	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-general-administrative	131.88	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-and-marketing-expenses	0	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-expenses	-0.36	-0.4	-0.1	-0.1	0.2	-0.1	0	-0.1	0	0	0	0	0	0
income-statement-row.row.operating-expenses	270.55	270.1	294.1	304.7	277.2	227.8	210.2	132.1	110.9	119.3	76.1	34.3	16.5	10.5
income-statement-row.row.cost-and-expenses	275.57	275.6	299.3	308.1	279.9	230.2	210.2	132.1	110.9	119.3	76.1	34.3	16.5	10.5
income-statement-row.row.interest-income	10.94	10.9	2.4	0.6	2.8	5.4	4	1.7	1.3	0.9	0.1	0	0	0
income-statement-row.row.interest-expense	23.82	23.8	25	26	27.1	15.6	2.5	-1.6	-1.3	-0.9	0	0	0	0
income-statement-row.row.selling-and-marketing-expenses	0	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.total-other-income-expensenet	-6.95	-13.2	-22.7	-25.5	-24.1	-10.3	1.5	-0.1	0	0	0	0	0	0
income-statement-row.row.ebitda-ratio-caps	0	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-operating-expenses	-0.36	-0.4	-0.1	-0.1	0.2	-0.1	0	-0.1	0	0	0	0	0	0
income-statement-row.row.total-operating-expenses	-6.95	-13.2	-22.7	-25.5	-24.1	-10.3	1.5	-0.1	0	0	0	0	0	0
income-statement-row.row.interest-expense	23.82	23.8	25	26	27.1	15.6	2.5	-1.6	-1.3	-0.9	0	0	0	0
income-statement-row.row.depreciation-and-amortization	5.58	0.5	2.3	0.5	3	5.4	4	0.7	0.7	0.6	0.3	0.1	0.1	0.1
income-statement-row.row.ebitda-caps	-121.1	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.operating-income	-129.54	-129.5	-142.2	-98.3	-171.8	-189.3	-179.9	-130.5	-110.7	-119.1	-75.8	-34	-15.9	-10.3
income-statement-row.row.income-before-tax	-142.78	-142.8	-164.9	-123.8	-196	-199.6	-178.4	-128.9	-109.4	-118.2	-75.8	-33.9	-15.9	-10.3
income-statement-row.row.income-tax-expense	0.32	0.3	0.4	0.3	0.3	0	0	0.1	0.1	-0.9	-0.1	0	0	0
income-statement-row.row.net-income	-143.1	-143.1	-165.3	-124.1	-196.3	-199.6	-178.4	-129	-109.6	-118.2	-75.8	-33.9	-15.9	-10.3